We have located links that may give you full text access.
Transauricular Vagus Nerve Stimulation (taVNS) enhances CPM in healthy subjects: A randomized controlled trial.
Brain Stimulation 2024 March 6
BACKGROUND: Evidence suggests that transauricular vagus nerve stimulation (taVNS) modulates the endogenous pain system and may be an alternative treatment for chronic pain conditions.
OBJECTIVE: To investigate the effects of taVNS in pain processing using quantitative sensory testing (QST) as a biomarker for pain sensitivity and modulation.
METHODS: We conducted a randomized double-blinded controlled study with 44 healthy subjects, 22 allocated to taVNS and 22 to sham taVNS. QST metrics (pain-60, temporal summation [TSPS], and conditioned pain modulation [CPM]) were the main outcomes of the study. Self-reported mood and fatigue were secondary outcomes. We performed regression analyses to evaluate the differences between pain-60 scores, TSPS, and CPM before and after intervention comparing taVNS and sham VNS groups. Moreover, Bayesian models were performed as sensitivity analysis.
RESULTS: Our findings showed a statistically significant difference in the CPM score between taVNS and sham taVNS (beta coefficient = 0.80; 95% CI: 0.23-1.37; p = 0.007). The effect size (Cohen's d) of this difference was 0.97, which is considered a large effect size. Bayesian results (non-informative prior) supported the superiority of taVNS showing a strong probability of benefit (99.99%; beta coefficient = 0.80; 95% CrI: 0.25-1.35; BF = 234.29). No differences were found in pain-60 (unadjusted: p = 0.58; adjusted: p = 0.76) or TSPS (unadjusted: p = 0.25; adjusted: p = 0.40). Moreover, the analysis demonstrated a significant correlation between VAS fatigue and mood with CPM improvement in the taVNS group. Also, changes in fatigue significantly mediated taVNS effects.
CONCLUSIONS: This study supports the taVNS positive effects on endogenous pain modulation in health subjects. Future RCTs using VNS in patients with chronic pain are still needed to establish the analgesic effects of taVNS in the clinical setting.
TRIAL REGISTRATION: NCT05801809.
OBJECTIVE: To investigate the effects of taVNS in pain processing using quantitative sensory testing (QST) as a biomarker for pain sensitivity and modulation.
METHODS: We conducted a randomized double-blinded controlled study with 44 healthy subjects, 22 allocated to taVNS and 22 to sham taVNS. QST metrics (pain-60, temporal summation [TSPS], and conditioned pain modulation [CPM]) were the main outcomes of the study. Self-reported mood and fatigue were secondary outcomes. We performed regression analyses to evaluate the differences between pain-60 scores, TSPS, and CPM before and after intervention comparing taVNS and sham VNS groups. Moreover, Bayesian models were performed as sensitivity analysis.
RESULTS: Our findings showed a statistically significant difference in the CPM score between taVNS and sham taVNS (beta coefficient = 0.80; 95% CI: 0.23-1.37; p = 0.007). The effect size (Cohen's d) of this difference was 0.97, which is considered a large effect size. Bayesian results (non-informative prior) supported the superiority of taVNS showing a strong probability of benefit (99.99%; beta coefficient = 0.80; 95% CrI: 0.25-1.35; BF = 234.29). No differences were found in pain-60 (unadjusted: p = 0.58; adjusted: p = 0.76) or TSPS (unadjusted: p = 0.25; adjusted: p = 0.40). Moreover, the analysis demonstrated a significant correlation between VAS fatigue and mood with CPM improvement in the taVNS group. Also, changes in fatigue significantly mediated taVNS effects.
CONCLUSIONS: This study supports the taVNS positive effects on endogenous pain modulation in health subjects. Future RCTs using VNS in patients with chronic pain are still needed to establish the analgesic effects of taVNS in the clinical setting.
TRIAL REGISTRATION: NCT05801809.
Full text links
Related Resources
Trending Papers
Systemic lupus erythematosus.Lancet 2024 April 18
Should renin-angiotensin system inhibitors be held prior to major surgery?British Journal of Anaesthesia 2024 May
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app